ACR/EULAR SLE Classification Criteria 2019
2019 EULAR/ACR classification criteria for SLE: positive ANA (entry criterion), then weighted criteria in 7 clinical and 3 immunology domains — only the highest criterion in each domain counts. At least one clinical criterion and 10 or more points classify SLE. Count a criterion only if nothing explains it better than SLE; criteria need not occur at the same time.
Score interpretation
The criteria need at least one clinical criterion (constitutional, haematological, neuropsychiatric, mucocutaneous, serosal, musculoskeletal or renal); immunology alone does not classify SLE.
→ Follow up ANA-positive patients with SLE-specific antibodies; rheumatology opinion if clinical suspicion.
Without ANA ≥ 1:80 at least once, the 2019 criteria cannot classify SLE.
→ Repeat ANA (HEp-2) if clinical suspicion; consider other connective tissue diseases; rheumatology opinion.
Score <10: Does not meet 2019 ACR/EULAR classification for SLE
→ Consider other connective tissue diseases; follow up ANA-positive patients; rheumatology opinion if clinical suspicion
Score ≥10: Meets 2019 ACR/EULAR criteria for SLE (requires positive ANA)
→ Rheumatology referral; baseline renal function, urinalysis, complement, anti-dsDNA; consider hydroxychloroquine; organise organ-specific investigations
Interpretation bands for the SLE Criteria 2019. Apply clinical judgement and local guidance.
References
- Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.
Related
Curated clinical cross-links plus same-class fallbacks.
- Hydroxychloroquine · Antimalarial — Lupus / Dermatoses
- Belimumab (Cutaneous Lupus) · BLyS/BAFF Inhibitor (Anti-B-Lymphocyte Stimulator)
- Lissamine Green 1% Eye Drops · Vital Dye — Ocular Surface Staining (Dry Eye Diagnosis)
- Cyclophosphamide (Nephrology) · ANCA Vasculitis / Lupus Nephritis
- Belimumab (Lupus Nephritis) · Lupus Nephritis
- Voclosporin · Lupus Nephritis
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.